Recent News

• 08.06.2026 - MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 07.07.2026 - MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
• 11.13.2025 - MeiraGTx Reports Third Quarter 2025 Financial and Operational Results
• 11.10.2025 - MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
• 10.07.2025 - MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
• 08.14.2025 - MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
• 08.14.2025 - MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
• 08.14.2025 - MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
• 06.09.2025 - Goldman Sachs 46th Annual Global Healthcare Conference
• 06.09.2025 - Goldman Sachs 46th Annual Global Healthcare Conference

Recent Filings

• 07.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.21.2026 - 144 Report of proposed sale of securities
• 07.07.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.07.2026 - 144 Report of proposed sale of securities
• 07.07.2026 - 8-K Current report
• 07.07.2026 - EX-99.1 EX-99.1
• 06.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.29.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.29.2026 - 4 Statement of changes in beneficial ownership of securities